|Day Low/High||102.00 / 103.08|
|52 Wk Low/High||92.09 / 119.21|
Carlisle Companies Incorporated (NYSE:CSL) will release first quarter 2018 results on Tuesday, April 24, 2018 after the market closes.
Carlisle Companies Incorporated (NYSE:CSL) announced today that it has completed the sale of Carlisle FoodService Products to The Jordan Company of New York, NY, for cash at an enterprise value of $750 million.
Global biotech leader rated at no. 42 for Patient Focus, Innovation, and Sustainable Growth
First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP
Life Sciences Pennsylvania recognized CSL Behring's commitment to patients for its novel subcutaneous C1 esterase inhibitor, HAEGARDA®, to prevent swelling caused by the rare genetic disorder
- Industry's role in ensuring access to medicine is an imperative, not an afterthought
Carlisle Companies Incorporated (NYSE:CSL) reported record fourth quarter 2017 net sales of $1,071.
The free market is going to take back control of interest rates.
The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) today announced a new share repurchase program that authorizes management to buy back up to an additional 5 million shares of the company's common stock...
Carlisle Companies Incorporated (NYSE:CSL) today announced the signing of a definitive agreement to sell Carlisle FoodService Products (CFS) to The Jordan Company of New York, NY, for $750 million in cash, subject to...
Carlisle Companies Incorporated (NYSE:CSL) will release fourth quarter 2017 results on Thursday, February 8, 2018 after the market closes.
Carlisle Companies Incorporated (NYSE: CSL) announced today that Jesse Singh, Chief Executive Officer of CPG International, has been elected to its Board of Directors, effective immediately.
Jim Cramer's bullish on Ford Motor, Cadence Systems, Carlisle, Teledyne, McDonald's.
Go ahead, call Jim Cramer a worry wart. But he wants investors to be prepared for anything. Here's his list of the Top 10 Investment Worries for 2018.
Study to evaluate CSL112 for the reduction of early, recurrent cardiovascular events in heart attack survivors
Seqirus partners with American Nurse Practitioner Foundation, American Pharmacists Association and Physician Assistant Foundation to drive conversation around flu prevention in adults 65 and older
Carlisle Companies Incorporated (NYSE:CSL) announced today that it has successfully closed an underwritten public offering of $1,000,000,000 aggregate principal amount of senior notes, consisting of $400,000,000 aggregate...
Hizentra PATH study, the largest controlled clinical study in patients with CIDP, met its primary endpoint
Carlisle Companies Incorporated (NYSE:CSL) announced today that D.
Carlisle Companies Inc. (NYSE:CSL) announced today that it has completed the purchase of Accella Performance Materials for $670 million in an all-cash transaction, pursuant to the previously announced purchase agreement...
A subgroup analysis of data from the Phase III COMPACT trial showed a 98 percent median reduction in hereditary angioedema (HAE) attacks per month in subjects who experienced at least one attack per week while on placebo(1)
Carlisle Companies Incorporated (NYSE:CSL) reported record net sales of $1,089.
Carlisle Companies Inc. (NYSE:CSL) is pleased to announce the appointment of Shelley Bausch as President of Carlisle Fluid Technologies, effective immediately.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.